What is short bowel syndrome?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 6, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

What is Short Bowel Syndrome?

Short bowel syndrome (SBS) is a devastating malabsorptive disorder that occurs when residual small intestinal length falls to 200 cm or less (measured from the duodenojejunal flexure), resulting from surgical resection or disease, leading to insufficient digestive and absorptive surface area. 1

Definition and Diagnostic Criteria

  • SBS is defined by a residual small intestinal length of ≤200 cm, though some experts suggest ≤150 cm may be more clinically appropriate 1
  • The bowel length must be measured along the antimesenteric border of unstretched bowel at the time of surgery, from the duodenojejunal flexure to either the ileocecal junction, the site of small bowel-colon anastomosis, or the end-ostomy 1
  • Surgeons must report residual bowel length, not resected length, as only the former dictates clinical outcome 1

Key Distinction: SBS vs Intestinal Failure

It is critical to understand that SBS and intestinal failure (IF) are not synonymous, though they are frequently confused 1:

  • SBS refers to the anatomic loss of intestinal length 1
  • Intestinal failure is defined functionally as reduction of gut function below the minimum necessary for absorption of macronutrients, water, and electrolytes, requiring intravenous supplementation (typically parenteral nutrition) to maintain health or growth 1
  • Most IF cases result from SBS, but IF can also occur from chronic intestinal pseudo-obstruction and refractory malabsorptive syndromes without anatomic shortening 1
  • Patients with reduced absorptive function who do not require IV supplementation have "intestinal insufficiency or deficiency" rather than intestinal failure 2

Clinical Manifestations

General Consequences

The predictable consequences stem from loss of digestive and absorptive surface area 1:

  • Diarrhea (often severe and high-volume) 1
  • Dehydration and fluid losses 1
  • Electrolyte abnormalities (particularly sodium, magnesium, and potassium) 1
  • Weight loss and malnutrition in the longer term 1
  • Fatty stools (steatorrhea) 2

Region-Specific Consequences

Specific deficiencies depend on which gastrointestinal segments are missing 1:

  • Terminal ileum resection causes vitamin B12 deficiency and bile acid-induced diarrhea 1
  • Duodenal loss impairs iron absorption 3
  • These anatomic clues provide critical guidance for targeted management 1

Anatomic Classification

The remaining bowel anatomy is the single most important prognostic factor and dictates management strategy 1:

Group 1: End-Jejunostomy

  • Most severe phenotype with worst prognosis 1
  • High-output jejunostomies are the most challenging SBS patients to manage 1
  • Patients lose the colon's critical role in water and electrolyte absorption 1

Group 2: Jejunocolonic Anastomosis

  • Jejunum connected to partial colon 1
  • Intermediate prognosis 1

Group 3: Jejuno-Ileo-Colic Anastomosis

  • Most favorable anatomic phenotype 1
  • Entire colon and ileocecal valve retained 1
  • The colon becomes an important digestive organ in SBS, enhancing intestinal adaptation and energy salvage 3, 4

Etiology

Adults

  • Massive intestinal resection is the most common cause 5
  • Vascular diseases (mesenteric ischemia) 6
  • Inflammatory bowel disease (particularly Crohn's disease) 6
  • Neoplasms 6

Children

  • Congenital anomalies predominate 7
  • Necrotizing enterocolitis 7

Epidemiology

  • SBS-IF is a rare disease 8
  • Estimated prevalence in 2024 ranges from 0.12 to 2.74 per 100,000 in adults 8
  • Estimated prevalence in children ranges from 0.09 to 1.67 per 100,000 8
  • Prevalence estimates are generally lower in countries with lower average income 8
  • Approximately 20-30% of SBS-IF patients develop intestinal failure-associated liver disease 9

Prognosis and Natural History

  • SBS is a chronic disease requiring evolving management strategies over time 10
  • Approximately 50% of SBS patients will achieve parenteral nutrition independence with appropriate management and intestinal adaptation 10
  • The remaining 50% progress to chronic intestinal failure requiring long-term parenteral support and potentially more aggressive interventions 10

References

Research

Definition, classification, and causes of short bowel syndrome.

Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition, 2023

Research

Short Bowel Syndrome in Adults.

The American journal of gastroenterology, 2022

Research

Understanding short bowel syndrome: Current status and future perspectives.

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2020

Research

Short bowel syndrome: Complications and management.

Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition, 2023

Research

Global prevalence of short bowel syndrome-associated intestinal failure in adults and children: A targeted literature review and analysis.

Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition, 2025

Research

Management of Short Bowel Syndrome (SBS) and Intestinal Failure.

Digestive diseases and sciences, 2023

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.